Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00759135 · ClinicalTrials.gov registry record · Phase 2
Phase 2 Study of NX-1207 for the Treatment of Benign Prostatic Hyperplasia (BPH) (Enlarged Prostate)
A Phase 2 study, sponsored by Nymox Corporation.
- Completed
- Registry status
- Phase 2
- Development phase
- 85
- Enrollment target
NCT00759135: Completed Phase 2 study, sponsored by Nymox Corporation.
NCT00759135 is a Phase 2 study that has completed, run by Nymox Corporation. The registered enrollment target is 85 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00759135, a Phase 2 study, has completed, sponsored by Nymox Corporation.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 85 participants
- Enrollment target
Study Summary
This completed study evaluated the safety and efficacy of two dose levels of NX-1207 for the treatment of BPH (benign prostatic hyperplasia) versus finasteride.
Interventions
- DRUG 2.5 mg NX-1207
- DRUG 0.125 mg NX-1207
- DRUG finasteride
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 85 participants |
| Start Date | 2007-05 |
| Est. Completion | 2008-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00759135
The ClinicalTrials.gov registry entry for NCT00759135 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 85 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Nymox Corporation, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which 2.5 mg NX-1207 is the first listed.
NCT00759135 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00759135 about?
NCT00759135 is a clinical study titled "Phase 2 Study of NX-1207 for the Treatment of Benign Prostatic Hyperplasia (BPH) (Enlarged Prostate)". This completed study evaluated the safety and efficacy of two dose levels of NX-1207 for the treatment of BPH (benign prostatic hyperplasia) versus finasteride.
What is the current status of trial NCT00759135?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 85 participants. The study started on 2007-05. Estimated completion is 2008-05.
What interventions are being tested in trial NCT00759135?
The interventions under investigation include: 2.5 mg NX-1207 (DRUG), 0.125 mg NX-1207 (DRUG), finasteride (DRUG).
Who is sponsoring clinical trial NCT00759135?
This trial is sponsored by Nymox Corporation, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.